Ralph McKenzie, DO
Psychiatry · Roanoke, VANPI 1932596897
Payments from drug & device makers
Across 952 payments — averaging $168.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$135K
- Vanda Pharmaceuticals Inc.$16K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Johnson & Johnson$774
- Teva Pharmaceuticals USA, Inc.$752
- plus $5K from 20 others
What the payments were for
- Speaking & faculty fees$142,07088%
- Travel & lodging$5,1463%
- Food & beverage$13,3388%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 365 | $135,490 |
| Vanda Pharmaceuticals Inc. | 59 | $16,022 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 107 | $1,626 |
| Otsuka America Pharmaceutical, Inc. | 59 | $1,066 |
| Johnson & Johnson | 38 | $774 |
| Teva Pharmaceuticals USA, Inc. | 50 | $752 |
| Takeda Pharmaceuticals U.S.A., Inc. | 50 | $715 |
| Lundbeck LLC | 43 | $712 |
| Neurocrine Biosciences, Inc. | 34 | $574 |
| Supernus Pharmaceuticals, Inc. | 9 | $499 |
| Axsome Therapeutics, Inc. | 24 | $423 |
| Alkermes, Inc. | 17 | $393 |
| Bausch Health US, LLC | 25 | $371 |
| Sunovion Pharmaceuticals Inc. | 23 | $300 |
| Almatica Pharma LLC | 13 | $272 |
| Idorsia Pharmaceuticals US Inc | 9 | $158 |
| Tris Pharma Inc | 8 | $145 |
| E.r. Squibb & Sons, L.L.C. | 6 | $118 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 3 | $70 |
| Noven Therapeutics, LLC | 3 | $50 |
| Neos Therapeutics, LP | 2 | $30 |
| Sun Pharmaceutical Industries Inc. | 1 | $22 |
| Avanir Pharmaceuticals, Inc. | 1 | $20 |
| Abbott | 1 | $18 |
| Corium, LLC | 1 | $18 |
| Eisai Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$160,654 in reported general payments places this provider in the 95th percentile of 884 psychiatry providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 32 | $67,508 |
| SpravatoEsketamine Hcl | 23 | $60,117 |
| Invega SustennaPaliperidone Palmitate | 12 | $41,362 |
| TrintellixVortioxetine Hydrobromide | 19 | $17,803 |
| RexultiBrexpiprazole | 11 | $15,171 |
| BelsomraSuvorexant | 12 | $5,064 |
| Divalproex Sodium ErDivalproex Sodium | 55 | $2,374 |
| Duloxetine Hcl | 72 | $2,022 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 60 | $1,614 |
| Trazodone Hcl | 154 | $1,409 |
| Bupropion XlBupropion Hcl | 94 | $1,387 |
| Quetiapine Fumarate | 55 | $1,313 |
| Mirtazapine | 61 | $1,215 |
| Clonazepam | 209 | $1,204 |
| Escitalopram Oxalate | 84 | $984 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato, Invega Sustenna | $774 | $101,48035 claims |
| AbbVieVraylar | $135,490 | $67,50832 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $715 | $17,80319 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,066 | $15,17111 claims |
| Almatica Pharma LLCSertraline Hcl | $272 | $63187 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 884 psychiatry providers in Virginia.
Other psychiatry in Roanoke
- David ScheidererRoanoke$2.4M
- Anita KablingerRoanoke$333K
- Roopa SethiRoanoke$49K
- Albert AriasRoanoke$20K
- Niku SinghFalls Church$2.5M
- Kent McDanielGlen Allen$2.1M
- Jasdeep MiglaniManassas$958K
- Frederick MoellerRichmond$678K
- David SpiegelNorfolk$565K
- Christopher van EyckStafford$392K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.